5-year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen: N03CC (Alliance)

BACKGROUND: Postmenopausal women with breast cancer (BC) receiving aromatase inhibitors are at increased risk for bone loss. The current study was undertaken to determine whether upfront versus delayed treatment with zoledronic acid (ZA) impacted bone loss. This report describes the 5-year follow-up...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer
Auteurs principaux: Wagner-Johnston, Nina D., Sloan, Jeff A., Liu, Heshan, Kearns, Ann E., Hines, Stephanie L., Puttabasavaiah, Suneetha, Dakhil, Shaker R., Lafky, Jacqueline M., Perez, Edith A., Loprinzi, Charles L.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512885/
https://ncbi.nlm.nih.gov/pubmed/25930719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29327
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires